Mega Contracts Monitor ($100M+) — May 21, 2026

Leidos Holdings subsidiary won a $432.5 million cost-plus-fixed-fee delivery order from NIH to operate a GOCO R&D facility, providing a stable multi-year revenue stream through May 2026 with low profit volatility due to the pricing structure.

Only $1.15 million of the $432.5 million contract has been outlayed as of the award date, indicating early-stage execution risk. If outlay rates do not accelerate, the full contract value may not materialize, reducing Leidos' expected annual revenue contribution of $64.6 million.

This single contract represents a significant civilian R&D revenue stream for Leidos, but with only $1.15 million outlayed, it concentrates execution risk in one GOCO facility operation. Any operational issues at the Frederick, MD facility could impact Leidos' overall government services portfolio.

Leidos can leverage this NIH GOCO contract to deepen its life sciences R&D footprint within the Department of Health and Human Services, potentially winning follow-on task orders or extensions beyond May 2026. The stable NIH funding environment supports long-term contract durability.

The $432.5 million NIH award to Leidos underscores the durability of GOCO facility operations in the civilian sector, where agencies like NIH provide consistent appropriations for mission-critical R&D infrastructure, contrasting with volatile defense procurement cycles.

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"The $432.5 million NIH contract is a large civilian award for Leidos, but the minimal outlay to date requires monitoring to confirm revenue realization. The contract's cost-plus structure provides stability but caps margin expansion.", "trigger"=>"Quarterly outlay rate disclosures; NIH budget markups in FY2025 appropriations bills; contract modification announcements"}